Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer

Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer

At the present time, a small group of patients with oligometastases (who have a solitary metastatic lesion in another organ along with the primary tumour of the lung) is differentiated among the patients with metastatic lung cancer. A total of 14 patients of the study citied in this article underwen...

Full description

Bibliographic Details
Main Authors: D. I. Yudin, K. K. Laktionov, D. T. Marinov, V. V. Breder, A. K. Allakhverdiev, T. N. Borisova, A. H. Bekyashev, K. P. Laktionov, V. A. Aleshin, M. S. Ardzinba
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-11-01
Series:Медицинский совет
Subjects:
nsclc
oligometastatic disease
lung cancer
Online Access:https://www.med-sovet.pro/jour/article/view/2759
Description
Summary:At the present time, a small group of patients with oligometastases (who have a solitary metastatic lesion in another organ along with the primary tumour of the lung) is differentiated among the patients with metastatic lung cancer. A total of 14 patients of the study citied in this article underwent a comprehensive treatment of oligometastatic non-small cell lung cancer (ONSCLC), which included systemic therapy and local influence on solitary metastasis. The median overall survival for this group was 20 months (16.0–32.6, CI 95%). The 1-year and 2-year overall survival rates accounted for 84.5 and 65.7%, respectively. The findings of the study demonstrate the possibilities of an aggressive approach to the treatment of patients with ONLDLC.
ISSN:2079-701X
2658-5790

Similar Items